Patient reported outcome measures| Volume 116, ISSUE 2, P179-184, August 2015

Download started.


Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy


      Background and purpose

      Stereotactic body radiotherapy (SBRT) is being used for prostate cancer, but concerns persist about toxicity compared to other radiotherapy options.

      Materials and methods

      We conducted a multi-institutional pooled cohort analysis of patient-reported quality of life (QOL) [EPIC-26] before and after intensity-modulated radiotherapy (IMRT), brachytherapy, or SBRT for localized prostate cancer. Data were analyzed by mean domain score, minimal clinically detectable difference (MCD) in domain score, and multivariate analyses to determine factors associated with domain scores at 2-years.


      Data were analyzed from 803 patients at baseline and 645 at 2-years. Mean declines at 2-years across all patients were −1.9, −4.8, −4.9, and −13.3 points for urinary obstructive, urinary incontinence, bowel, and sexual symptom domains, respectively, corresponding to MCD in 29%, 20%, and 28% of patients. On multivariate analysis (vs. IMRT), brachytherapy had worse urinary irritation at 2-years (−6.8 points, p < 0.0001) but no differences in other domains (p > 0.15). QOL after SBRT was similar for urinary (p > 0.5) and sexual domains (p = 0.57), but was associated with better bowel score (+6.7 points, p < 0.0002).


      QOL 2-years after brachytherapy, IMRT, or SBRT is very good and largely similar, with small differences in urinary and bowel QOL that are likely minimized by modern techniques.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sanda M.G.
        • Dunn R.L.
        • Michalski J.
        • Sandler H.M.
        • Northouse L.
        • Hembroff L.
        • et al.
        Quality of life and satisfaction with outcome among prostate-cancer survivors.
        N Eng J Med. 2008; 358: 1250-1261
        • Chen R.C.
        • Clark J.A.
        • Talcott J.A.
        Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function.
        J Clin Oncol. 2009; 27: 3916-3922
        • Ferrer M.
        • Suarez J.F.
        • Guedea F.
        • Fernandez P.
        • Macias V.
        • Marino A.
        • et al.
        Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2008; 72: 421-432
        • Ferrer M.
        • Guedea F.
        • Suarez J.F.
        • de Paula B.
        • Macias V.
        • Marino A.
        • et al.
        Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up.
        Radiother Oncol. 2013; 108: 306-313
        • Vogelius I.R.
        • Bentzen S.M.
        Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?.
        Int J Radiat Oncol Biol Phys. 2013; 85: 89-94
        • Chen L.N.
        • Suy S.
        • Uhm S.
        • Oermann E.K.
        • Ju A.W.
        • Chen V.
        • et al.
        Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
        Radiat Oncol. 2013; 8: 58
        • Hodges J.C.
        • Lotan Y.
        • Boike T.P.
        • Benton R.
        • Barrier A.
        • Timmerman R.D.
        Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer.
        J Oncol Pract. 2012; 8: e31s-37s
        • Amin N.P.
        • Sher D.J.
        • Konski A.A.
        Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
        Appl Health Econ Health Policy. 2014; 12: 391-408
        • Yu J.B.
        • Cramer L.D.
        • Herrin J.
        • Soulos P.R.
        • Potosky A.L.
        • Gross C.P.
        Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.
        J Clin Oncol. 2014;
        • D’Amico A.V.
        Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: less cost at the expense of more genitourinary toxicity is a concerning but testable hypothesis.
        J Clin Oncol. 2014;
        • Kim D.W.
        • Cho L.C.
        • Straka C.
        • Christie A.
        • Lotan Y.
        • Pistenmaa D.
        • et al.
        Predictors of rectal tolerance observed in a dose-escalated phase 1–2 trial of stereotactic body radiation therapy for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2014; 89: 509-517
        • King C.R.
        • Collins S.
        • Fuller D.
        • Wang P.C.
        • Kupelian P.
        • Steinberg M.
        • et al.
        Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.
        Int J Radiat Oncol Biol Phys. 2013; 87: 939-945
        • Bhattasali O.
        • Chen L.N.
        • Woo J.
        • Park J.W.
        • Kim J.S.
        • Moures R.
        • et al.
        Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
        Radiati oncol. 2014; 9: 52
        • Katz A.J.
        • Santoro M.
        • Diblasio F.
        • Ashley R.
        Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.
        Radiat Oncol. 2013; 8: 118
        • Wiegner E.A.
        • King C.R.
        Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trial.
        Int J Radiat Oncol Biol Phys. 2010; 78: 442-448
        • Hamstra D.A.
        • Conlon A.S.
        • Daignault S.
        • Dunn R.L.
        • Sandler H.M.
        • Hembroff A.L.
        • et al.
        Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience.
        Int J Radiat Oncol Biol Phys. 2013; 86: 546-553
        • Mantz C.A.F.
        • Zucker I.
        • Harrison S.
        A phase II trial of real-time target tracking sbrt for low-risk prostate cancer utilizing the calypso 4D localization system: patient-reported quality of life and toxicity outcomes.
        Int J Radiat Oncol Biol Phys. 2011; 81: S100
        • Wei J.T.
        • Dunn R.L.
        • Litwin M.S.
        • Sandler H.M.
        • Sanda M.G.
        Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
        Urology. 2000; 56: 899-905
        • Ware Jr., J.
        • Kosinski M.
        • Keller S.D.
        A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity.
        Med Care. 1996; 34: 220-233
        • Skolarus T.A.
        • Dunn R.L.
        • Sanda M.G.
        • Chang P.
        • Greenfield T.K.
        • Litwin M.S.
        • et al.
        Minimally important difference for the expanded prostate cancer index composite short form.
        Urology. 2015; 85: 101-106
        • Crook J.M.
        • Gomez-Iturriaga A.
        • Wallace K.
        • Ma C.
        • Fung S.
        • Alibhai S.
        • et al.
        Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial.
        J Clin Oncol. 2011; 29: 362-368
        • Barry M.J.
        • Fowler Jr., F.J.
        • O’Leary M.P.
        • Bruskewitz R.C.
        • Holtgrewe H.L.
        • Mebust W.K.
        • et al.
        The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.
        J Urol. 1992; 148: 1549-1557
        • Potosky A.L.
        • Harlan L.C.
        • Stanford J.L.
        • Gilliland F.D.
        • Hamilton A.S.
        • Albertsen P.C.
        • et al.
        Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study.
        J Natl Cancer Inst. 1999; 91: 1719-1724
        • Potosky A.L.
        • Davis W.W.
        • Hoffman R.M.
        • Stanford J.L.
        • Stephenson R.A.
        • Penson D.F.
        • et al.
        Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
        J Natl Cancer Inst. 2004; 96: 1358-1367
        • Talcott J.A.
        • Manola J.
        • Chen R.C.
        • Clark J.A.
        • Kaplan I.
        • D’Amico A.V.
        • et al.
        Using patient-reported outcomes to assess and improve prostate cancer brachytherapy.
        BJU Int. 2013;
        • Sandler H.M.
        • Liu P.Y.
        • Dunn R.L.
        • Khan D.C.
        • Tropper S.E.
        • Sanda M.G.
        • et al.
        Reduction in patient-reported acute morbidity in prostate cancer patients treated with 81-Gy Intensity-modulated radiotherapy using reduced planning target volume margins and electromagnetic tracking: assessing the impact of margin reduction study.
        Urology. 2010; 75: 1004-1008
        • Vainshtein J.
        • Abu-Isa E.
        • Olson K.B.
        • Ray M.E.
        • Sandler H.M.
        • Normolle D.
        • et al.
        Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy.
        Radiat Oncol. 2012; 7: 82
        • Miller D.C.
        • Sanda M.G.
        • Dunn R.L.
        • Montie J.E.
        • Pimentel H.
        • Sandler H.M.
        • et al.
        Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.
        J Clin Oncol. 2005; 23: 2772-2780
        • Liauw S.L.
        • Weichselbaum R.R.
        • Rash C.
        • Correa D.
        • Al-Hallaq H.A.
        • Pelizzari C.A.
        • et al.
        Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer.
        Technol Cancer Res Treat. 2009; 8: 201-206
        • Cho L.C.
        • Timmerman R.
        • Kavanagh B.
        Hypofractionated external-beam radiotherapy for prostate cancer.
        Prostate Cancer. 2013; 2013: 103547
        • Phan J.
        • Swanson D.A.
        • Levy L.B.
        • Kudchadker R.J.
        • Bruno T.L.
        • Frank S.J.
        Late rectal complications after prostate brachytherapy for localized prostate cancer: incidence and management.
        Cancer. 2009; 115: 1827-1839
      1. Phase III study of HYPOfractionated RadioTherapy of intermediate risk localised Prostate Cancer, <> (accessed 7/22/14).

      2. Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer, <> (accessed 7/22/14).

      3. International randomised study of laparoscopic prostatectomy vs stereotactic body radiotherapy (SBRT) and conventionally fractionated radiotherapy vs SBRT for early stage organ-confined prostate cancer, <> (accessed 5/6/2015).